Tag Archives: HEA

PR Newswire

Waterdrop Inc. Announces Earnings Date Change: First Quarter 2023 Earnings Release Scheduled June 2, 2023

Leave a comment

BEIJING, May 31, 2023 /PRNewswire/ — Waterdrop Inc. (NYSE: WDH) (“Waterdrop” or the “Company”), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2023, before U.S. markets open on Friday, June 2, 2023, instead of the previously announced date of June 5, 2023.

Waterdrop’s management team will hold a conference call on June 2, 2023 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:

International:

1-412-317-6061

United States Toll Free:

1-888-317-6003

Hong Kong Toll Free:

800-963976

Hong Kong:

852-58081995

Mainland China:

4001-206115

Chinese Line (Mandarin) Entry Number:

6683992

English Interpretation Line (Listen-only Mode) Entry Number:

8700524

Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.

Telephone replays will be accessible two hours after the conclusion of the conference call through June 9, 2023 by dialing the following numbers:

United States Toll Free:

1-877-344-7529

International:

1-412-317-0088

Chinese Line Access Code:

1702325

English Interpretation Line Access Code:

8201572

Additionally, live and archived webcasts of the conference call will be available at the Company’s investor relations website at http://ir.waterdrop-inc.com/.

About Waterdrop Inc.

Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.

For investor inquiries, please contact

Waterdrop Inc.
IR@shuidi-inc.com

Source: Waterdrop Inc.

PR Newswire

Frost & Sullivan Institute Announces the Launch of the 2023 Enlightened Growth Leadership Awards for Emerging Companies to Recognize Companies Driving a Sustainable Future

Leave a comment

SANTA CLARA, Calif., May 3, 2023 /PRNewswire/ — Frost & Sullivan Institute, in partnership with Frost & Sullivan announces the launch of the Enlightened Growth Leadership Awards, 2023 – Emerging Companies* edition. The award recognizes emerging companies that drive transformation toward a sustainable future.

Frost & Sullivan Institute congratulates all the recipients of the Enlightened Growth Leadership Awards for Emerging Companies, 2023
Frost & Sullivan Institute congratulates all the recipients of the Enlightened Growth Leadership Awards for Emerging Companies, 2023

“The winning companies represent a diverse range of industries and geographies. However, they all share a deep commitment towards innovating global challenges to zero and a drive to create a positive impact through their products, services and business strategies,” said David Frigstad, Director, Frost & Sullivan Institute.

In order to identify companies that are setting the standard for sustainability, we use a rigorous eight-step methodology coupled with thought leadership and global think tanks. The company’s products and services are designed to address global challenges to zero in addition to achieving Growth Excellence. In honoring and celebrating companies that are promoting sustainable practices, we hope to inspire others to join this movement.

Frost & Sullivan Institute congratulates all the recipients of the Enlightened Growth Leadership Awards for Emerging Companies, 2023. We will recognize and celebrate the 2023 emerging company award recipients at our Virtual Awards Ceremony in June.

*For the purpose of this award, we define Emerging Companies as companies that are 3-5 years in the market and have products/services focused on innovating global challenges to zero.

Recipients:

Alto

Ancala Water Services

Anduril

Armo Security

AUM Biosciences

Aura

Autokiniton Global Group

Axonius

BP Bunge Bioenergia

Calm (Therapeutic Devices)

Campus Energy Partners

Central Rivers Power

CentralSquare Technologies

Cityblock

Coalition

CommonSpirit Health

Converged Security Solutions

CyCraft Technologies

CYSEC

Easee (Electronics)

About Frost & Sullivan Institute

The Frost & Sullivan Institute (FSI) is a non-profit organization dedicated to utilizing business practices to address global priorities. The genesis of the institute goes back to the vision of either creating, or becoming part of, a solution that addresses threats to humanity. The Institute has identified strategic imperatives for transformation and believes that we can truly accelerate innovation to zero. To learn more about FSI, visit www.frostandsullivaninstitute.org

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Media Contact:

Prerna Mohan
Email: prerna.mohan@frost.com

SOURCE Frost & Sullivan

Related Links
www.frost.com 
www.frostandsullivaninstitute.org

PR Newswire

Jim Lim joins Zühlke Group as Head of Health & Medtech in Singapore

Leave a comment

SINGAPORE, April 21, 2023 /PRNewswire/ — Zühlke Group is pleased to announce the appointment of Jim Lim as Head of Market Unit (Health & Medtech) at Zühlke Asia. Based in Singapore, Jim will lead the organisation’s regional efforts to serve the healthcare industry and continue to expand Zühlke’s healthcare expertise and offerings to the ecosystems of healthcare providers, pharmaceutical and medtech companies in Asia.

Jim Lim, Head of Health & Medtech - Zühlke Asia
Jim Lim, Head of Health & Medtech – Zühlke Asia

With over 24 years of ICT industry experience, Jim brings his wealth of experience providing strategic, business and technological advice to global clients. Having held various senior leadership positions across MNCs, Jim has served clients across multiple industry verticals such as healthcare, pharmaceutical, medtech, telecommunications, financial services, education and manufacturing. Jim was also the founding CEO of Good Doctor Technology, a joint venture between Ping An Good Doctor, Grab and Softbank.

Outside his corporate career, Jim is the co-founder of a socio-techno network focused on bringing together the expertise, experiences and connections of senior executives globally to contribute back to society. He is appointed Senior Fellow by the Singapore University of Social Sciences and Executive Education Fellow by the National University of Singapore. He also serves as an industry mentor for Young NTUC and Vice President for Cloud Security Alliance Singapore Chapter.

Driving the future of health innovation through impactful work

Jonas Trindler, CEO Asia, Member of Group Executive Board & Partner of Zühlke Group, commented, “We’re actively contributing to significant breakthroughs in the health markets, with the pandemic accelerating digitalisation across health ecosystems. Together with our clients, we are solving critical challenges in this space to improve healthcare with quality and access. We are confident that Jim’s extensive experience and strategic leadership will enable us to drive further growth and meaningful innovation in the health and medtech space.”

“Asia is paving the way for next-generation digital healthcare and medtech ecosystems. I look forward to leading Zühlke’s health market at such an exciting time and contributing to impactful innovation to transform and provide sustainable healthcare to the everyday lives of people,” commenting on his new role, Jim said.

Zühlke – Empowering Ideas.

Zühlke is a global innovation service provider. We envisage ideas and create new business models for our clients by developing services and products based on new technologies – from the initial vision through development to deployment, production, and operation. We specialise in strategy and business innovation, digital solutions, and application services – in addition to device and systems engineering. Our outstanding solutions provide unique business value and a reliable foundation for sustained success.

Zühlke was founded in Switzerland in 1968 and is owned by its partners. Our 1,900 employees are based in Austria, Bulgaria, Germany, Hong Kong, Portugal, Serbia, Singapore, Switzerland, the United Kingdom and Vietnam, serving clients from a wide range of industries. In addition, our venture capital arm Zühlke Ventures provides start-up financing in the high-tech sector.

Contact: Lorraine Lai, lorraine.lai@zuhlke.com, +6569217800

PR Newswire

uLab® Launches the Orthodontics Industry’s First Suite of Practice-Branded Packaging Options

Leave a comment

MEMPHIS, Tenn., April 19, 2023 /PRNewswire/ — uLab Systems™, the creator of the uSmile™ clear aligner platform and the new uAssist™ concierge service, announces it now offers orthodontists a suite of branding options that give them the ability to create a variety of custom-designed packaging products that will enhance the patient experience and can help grow new business. Since 2021, uLab customers have benefited from the option to package a patient’s aligner in a box designed with the orthodontist’s name and/or logo. Now, the aligner pouch and aligner case can also perform as marketing platforms and will come as a custom-branded package with the box. In addition, orthodontists can now order branded typodonts and patient brochures for their in-office consultations. The new suite of custom options will be available in May.  

An example suite of custom logo items for patient aligner cases manufactured by uLab Systems for Wu Orthodontics.
An example suite of custom logo items for patient aligner cases manufactured by uLab Systems for Wu Orthodontics.

“The ability to brand the aligner package, pouch, and aligner case with our practice logo allowed us to provide the patient with a unique, personalized experience,” says Dr. Kevin Oliviera from Coastal Orthodontics, a member of the pilot group that trialed the customized items. “When a patient is presented with a custom-branded package, it reinforces the value of receiving a high-quality aligner that was designed by someone they know and trust. The patient’s confidence in us and their peace of mind are invaluable,” he adds. Dr. Oliviera also notes that the branded items are giving his/her practice much more visibility in the community. “They are terrific marketing tools that distinguish us from other practices.”

Orthodontists develop long-term relationships over the course of their career with the communities where they practice, even treating several generations of families.  “At uLab, we believe it’s more important that our customers promote their brand rather than the manufacturer’s,” says Amir Abolfathi, chief executive officer and co-founder of uLab.  “It is the orthodontist’s expertise and their patient care that help create beautiful smiles. uLab provides them with the innovative software tools and proven materials they need to develop an effective treatment, but it is ultimately up to them to create the smiles. Their brand and expertise are what patients should associate with quality results.”

uLab is dedicated to innovating for the orthodontic specialty, providing practitioners with easy access to innovative, state-of-the-art tools that enable the flexibility to control the patient treatment plan, unencumbered by pricing structure confines and restrictive protocols. The company has delivered on that commitment since its inception with the release of its in-office aligner design and printing software, uSmile aligners, the uAssist concierge service, and now its custom packaging capabilities. uLab has future plans for “all-digital” platform options, enhanced AI-guided planning tools, and features to enable direct print outputs.

uSmile aligners are manufactured in Memphis, Tennessee, and can be delivered in as few as three business days*. The uLab platform allows orthodontists ultimate control over their aligner treatments. More than 800,000 aligner treatment cases have been planned to date.

* Shipment times may vary depending on location and delivery time selection.

About uLab Systems
uLab Systems is led by an experienced team of healthcare innovators helping to transform options for orthodontic practices to provide the best outcomes for their patients. uLab’s mission is to advance the orthodontic industry with aligner products and digital treatment planning software that let orthodontists take back control of their treatment plans. To learn more visit www.ulabsystems.com. Contact: David Thrower, Chief Commercial Officer, pr@ulabsystems.com

© 2023 uLab Systems, Inc. All Rights Reserved. uLab Systems, uSmile, uAssist, uView, Smart Outcomes, and Smart Office are trademarks and uLab and uDesign are registered trademarks of uLab Systems, Inc. MAR-0001304 Rev 1
Now available! Orthodontists that want to promote their brand for patient aligner cases will now receive custom logo aligner pouches and an aligner case packaged with the custom logo box.
Now available! Orthodontists that want to promote their brand for patient aligner cases will now receive custom logo aligner pouches and an aligner case packaged with the custom logo box.

Photo – https://techent.tv/wp-content/uploads/2023/04/ulab-launches-the-orthodontics-industrys-first-suite-of-practice-branded-packaging-options-2.jpg
Photo – https://techent.tv/wp-content/uploads/2023/04/ulab-launches-the-orthodontics-industrys-first-suite-of-practice-branded-packaging-options.jpg
Logo – https://techent.tv/wp-content/uploads/2023/04/ulab-launches-the-orthodontics-industrys-first-suite-of-practice-branded-packaging-options-1.jpg

Source: uLab Systems, Inc.

PR Newswire

DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES RESIDENCY AT JLABS @ SHANGHAI

Leave a comment

SINGAPORE, April 10, 2023 /PRNewswire/ — Respiree announced today that it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’)[1] from February 21, 2023 , in order to expand its footprint with the goal of deepening its relationships and networks within the pharma and life science sector.

Respiree’s team at JLABS will focus on utilizing the iRIS One decentralized clinical trials platform with the aim to optimize drug trials and discover newer lung and cardiac digital biomarkers. Respiree’s team also aims to extend development of its novel digital therapeutics pipeline to incorporate real-world pharma evidence.

“We are very proud and excited to be joining the JLABS ecosystem. We hope to enhance the iRIS One clinical trials platform.  Through our expanded connectivity we also hope to further develop our digital therapeutics pipeline with the ultimate aim of enabling patients to access better treatments faster,” said Respiree’s CEO and Founder Dr Gurpreet Singh.

Respiree received the 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration (FDA) on 8 March 2023.

[1] Johnson & Johnson Innovation

About Respiree

Respiree is a digital therapeutics company providing personalized healthcare services for cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI and workflow integrated UIUX. Respiree is deployed internationally. Respiree’s iRIS One clinical trials platform is CE marked, approved for use in Australia by the Therapeutics Goods Administration and just received 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration.

PR Newswire

Picarro Cavity Ring-Down Spectroscopy Successfully Validated Under EPA’s OTM-47 to Measure Ethylene Oxide Emissions in Real-Time from Stationary Sources

Leave a comment

SANTA CLARA, Calif., April 5, 2023 /PRNewswire/ — Picarro, Inc. today announced the successful validation and use of the company’s Cavity Ring-Down Spectroscopy (CRDS) under Other Test Method 47 (OTM-47) as published by the Environmental Protection Agency (EPA) on March 23, 2023. The method describes the measurement of ethylene oxide (EtO or EO) emissions from stationary sources by CRDS. OTM-47 represents the first EtO specific real-time stack test method and will provide the industry with a reliable technique for demonstrating regulatory compliance.

CRDS is a highly sensitive analytical technology that can accurately measure trace levels of EtO emissions from source, stack, and ambient applications. The development of OTM-47 was conducted by third-party stack testing company, CleanAir Engineering, using multiple commercially available Picarro instruments, and through site-specific requests for the use of CRDS in performance testing at commercial sterilization facilities. Data gathered through EPA Method 301 validation of OTM-47 demonstrates that Picarro’s CRDS is a reliable and robust technology that can be used as an alternative to less precise technology-based methods such as optically enhanced Fourier Transform Infrared Spectroscopy (OE-FTIR), Gas Chromatography (GC), and passive techniques.

The successful validation of this method reaffirms Picarro’s ability to deliver accurate and reliable testing solutions to medical device and contract sterilization customers and chemical plants. Many incumbent technologies are complicated, expensive to maintain, and require large amounts of downtime due to frequent maintenance. Picarro CRDS operates by measuring the decay rate of light inside of a robust optical cavity using a coherent light source making its systems less susceptible to interference when measuring target gases such as EtO.

“We are excited to see the successful validation of CRDS under Other Test Method 47. This method will allow customers emitting ethylene oxide to generate more accurate and defensible data than other technologies, which is critical for ensuring compliance and mitigating regulatory risk,” said Joel Avrunin, Vice President of Environmental at Picarro.

About Picarro
Picarro is a leading provider of Cavity Ring-Down Spectroscopy (CRDS)-based, real-time monitoring solutions that offer advanced detection and data analytics technology. Picarro’s suite of systems provides end-to-end visibility with monitoring systems for stacks, indoor air, and fencelines that are supported by a team of experienced and highly qualified professionals who are committed to providing turn-key solutions to customers.  With more than 25 years of expertise and thousands of customers in nearly 100 countries, Picarro is a trusted and reliable partner in ensuring compliance with regulations and environmental standards. For more information, visit www.picarro.com.

Media Contacts:
Jake Thill
Director, Marketing Communications
Picarro, Inc.
jthill@picarro.com

Source: Picarro, Inc.

PR Newswire

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

Leave a comment

Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board

LONDON, March 24, 2023 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

Jonathan Gear, Chief Executive Officer, Clarivate said: “I’m very pleased to announce the appointment of Gordon who has been a trusted and valued member of our Executive Leadership Team since he came to Clarivate from CPA Global as part of our acquisition in 2020. In this newly created role, he will be responsible for accelerating the growth of our IP segment empowering customers to establish, protect and manage their IP.

Based on my experience working with him over the last eight months and the work we’ve done this year to align the organization, I’m confident that he will be instrumental to how we capitalize on product and service innovation to deliver organic growth. This is the first of our presidential appointments and we look forward to providing updates on further appointments in due course.”

Samson joined Clarivate in October 2020 with the acquisition of CPA Global, having joined CPA Global in 2014 as Chief Operating Officer. During the last three years with Clarivate, Samson has made significant contributions, helping transform the Company’s APAC region and bringing together the Company’s entire product portfolio to offer customers a full range of enriched data, insights, analytics and workflow solutions. He has a long and successful track record of driving organizational transformation and growth in the IP industry and beyond, having held senior executive roles with both operating and P&L accountability for more than 20 years.

Andy Snyder, Chairman of the Board, Clarivate commented: “We look forward to Dr. Saha joining our Board. He will bring a great deal of experience in the pharmaceutical and biotech industries and his guidance will provide valuable insights and perspective, especially as we continue to execute on our growth strategy in the Life Sciences & Healthcare segment.”

Dr. Saha is a physician-scientist, pharmaceutical executive, and biotech entrepreneur dedicated to discovering and developing novel life-changing medicines. He is notable for leading the development and demonstrating human effectiveness of two innovative cancer drugs, an ERK kinase inhibitor (Ulixertinib) and an oncolytic immunotherapy (C. novyi-NT). He is currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), a global pharma company. Prior to Centessa, Dr. Saha was a Senior Vice President of R&D and Global Head of Translational Medicine for all disease areas at Bristol Myers Squibb. Other past roles include Venture Partner at Atlas Venture, a VC firm in Cambridge MA, Chief Executive Officer at Delinia, Chief Medical Officer of Synlogic, a management consultant at McKinsey & Company, and head of the New Indications Discovery Unit at Novartis. He is an associate member and Global Clinical Scholar at Harvard Medical School, holds an MD and PhD in medicine and cancer genetics from The Johns Hopkins School of Medicine, an MSc in biophysics from the University of Oxford and a BSc in biochemistry from Caltech.

About Clarivate

Clarivate™ is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.

Investor Relations Contact
Mark Donohue, Head of Investor Relations, investor.relations@clarivate.com, +1 (215) 243 2202

Media Contact
Amy Bourke-Waite, Senior Director, Corporate Communications, newsroom@clarivate.com

PR Newswire

Martech platform Ortto celebrates record growth on the anniversary of its rebrand

Leave a comment

The unified customer data, analytics, and marketing automation platform Ortto, formerly Autopilot, continues to see double-digit monthly growth a year on from its rebrand. The martech company now has more than 3,000 customers globally and was recognized in 49 categories in G2’s biannual report.

SYDNEY, March 8, 2023 /PRNewswire/ — Ortto, which started as Autopilot Journeys in 2015, rebranded in early 2022 following the launch of a revolutionary new platform that allows marketers to effortlessly connect previously siloed data sources to get a complete view of their customers. Marketers can analyze and operationalize this data without the need for specialized support, enabling them to deliver personalized customer journeys at scale, increasing the impact of their campaigns with powerful event-based triggers and AI-content optimization. In the year since the rebrand, Ortto’s users have built some 5,000 journeys and sent more than 210 million emails to their customers, contributing to the  company’s sustained 16% month-on-month growth.

Ortto helps data-driven marketers easily build powerful reports to understand what’s working and make decisions with confidence. Dashboards allow teams to pin key reports to a shared space so they never lose sight of key metrics.
Ortto helps data-driven marketers easily build powerful reports to understand what’s working and make decisions with confidence. Dashboards allow teams to pin key reports to a shared space so they never lose sight of key metrics.

  • The powerful platform received the ‘High Performer’ badge in 11 categories in the G2 Winter 2023 reports, including marketing automation and marketing platform, across multiple regions (APAC, ANZ, Europe, UK, etc.)
  • Ortto was also awarded the ‘Best estimated ROI’ badge and the ‘Easiest to use’ badge in the customer journey mapping categories, as well as the ‘Users Love Us’ badge.
  • The platform was also ranked number one for data personalization by SoftwareReviews.

Customer, Mica Shtewi, Tech Manager at Pattern, comments:

“When you’re moving into a world we’re moving into, you have so many data sources that you’re trying to bring together and various communications to get clients moving through the sales process. We needed something flexible that works and had a robust integration with Salesforce, and with Ortto we can target people the way we want to target them.”

Visually design journeys that automate personalized messages and trigger actions across the customer lifecycle with Ortto.
Visually design journeys that automate personalized messages and trigger actions across the customer lifecycle with Ortto.

Michael Sharkey, CEO and co-founder of Ortto, comments:

“Everyone recognizes the importance of data in building better, more personalized customer experiences, but the problem is, for many businesses, this data is located across a number of different tools and isn’t easily accessible to marketers. That’s why we rebuilt our platform to make it easy to bring all of that data together in one place and remove the barriers to entry, so marketers have ready access to the data they need without having to lodge a ticket or learn SQL. The response to the new platform has been incredible – not only from our Autopilot customers, who are realizing new value through Ortto, but also from new customers who have come on board in the past year.”

About Ortto

Ortto, the world’s first complete marketing automation, AI and analytics platform, empowers marketers to act with confidence and increase their impact on revenue. By combining three powerful tools into one intuitive platform, teams finally benefit from their customer data, messaging, and analytics working together.

Sophisticated yet easy to use, more than 3,000 customers trust Ortto to understand their impact, discover their next marketing opportunity, and continuously iterate to deliver great customer experiences at scale. Learn more at: www.ortto.com 

Launched in 2015, Ortto’s team is located in Australia, Europe and the US. To date, the company has raised $35M in venture funding from backers including Blackbird, Rembrandt and Salesforce Ventures.

Source: Ortto, Inc.

PR Newswire

US proteomics sector set for shake-up as new IonOpticks tech unveiled

Leave a comment

IonOpticks to introduce the TS, a fully integrated column heating and interface solution for Thermo Scientific users

MELBOURNE, Australia, March 3, 2023 /PRNewswire/ — IonOpticks, a producer of high-performance chromatography solutions for the global research community, will introduce the new TS product range to the US market at US HUPO’s (US Human Proteome Organization) 19th Annual Conference in Chicago on 4-8th March, a renowned event attended by proteomics experts from around the globe.

IonOpticks’ new TS range was developed as a simple plug-and-play, fully integrated heating and source solution for Thermo Scientific mass spectrometer users, who have previously only been able to access the results achievable with IonOpticks Aurora Series columns by creating their own interface – a costly and difficult alternative.

“Researchers can now easily unlock the full potential of their mass specs through the launch of our new TS range. Thermo Orbitraps have been cited in roughly 85% of all publications related to proteomics in the last decade, so we’re excited to make our famed Aurora Series products easily accessible to this significant portion of the mass spec community,” says Xavier Perronnet, Managing Director at IonOpticks.

“We’re excited to be attending US HUPO, to meet with our peers and showcase how the TS, combined with our Aurora Series columns, can provide Thermo mass spec users the ability to supercharge the sensitivity of their existing instruments. Our columns enable researchers to delve deeper into their samples than ever before.” Mr Perronnet continues.

The combination of IonOpticks’ proprietary nanoZero® fittings and integrated emitter with the new TS range removes all pre- and post-column dead volume, maximizing the capacity of the chromatographic packed bed to separate samples. Further, the heating solution in the TS is reusable which saves users both time and money while reducing unnecessary waste.

The TS range was developed following the paradigm-shifting release of the Aurora Frontier – the first ever column to routinely generate over 10,000 protein identifications on a Thermo mass spectrometer – from a single sample and single species.

“The results that have been achieved with our Aurora Frontier have been outstanding and we’re proud to continue to develop products that enable us to ensure access to these gains is equal for all researchers,” says Dr Jarrod Sandow, Head of Product Development at IonOpticks.

“Thermo users continue to be top customers of our products, so we’ve worked hard behind the scenes to ensure these users can easily boost the performance of their existing instruments through a simple all-in-one heating and source integration system. One that requires no complex installation and is ready to use straight out of the box,” Dr Sandow adds.

IonOpticks is committed to ensuring the world’s best chromatography is available to all mass spec users. Alongside the TS, IonOpticks have also launched the SX, a fully integrated column heating and interface solution for SCIEX users.

About IonOpticks

IonOpticks produces high-performance chromatography solutions for the global research community.

We specialise in the development and manufacture of columns for analytical applications in liquid chromatography with mass spectrometry (LC-MS) and high-end proteomics. Our highly reproducible methods provide a unique ability to enhance the sensitivity of mass spectrometry sample analysis, enabling scientists and clinicians to discover more from their samples.

Our team are experts in a broad array of LC-MS platform technologies and are driven by the need to improve chromatographic performance in order to achieve data quality and deep proteome coverage on a whole new scale.

https://ionopticks.com/ / https://www.proteomicssolved.com/

Cision View original content:https://www.prnewswire.com/news-releases/us-proteomics-sector-set-for-shake-up-as-new-ionopticks-tech-unveiled-301760866.html

PR Newswire

CGTN: Reflecting on China’s Three-year COVID Battle in Through the Storm

Leave a comment

BEIJING, Feb. 10, 2023 /PRNewswire/ — Since early 2020, China has been following a unique path in combatting COVID-19. Through the Storm condenses this three-year battle into a 60-minute documentary.

This CGTN presentation has its global premiere on February 10. Through the Storm features first-hand accounts of the initial outbreak in Wuhan, the mass vaccination campaign, the Shanghai lockdown and, finally, the reopening and recovery.

Through the Storm answers three essential questions: What was China’s reasoning behind choosing its unique approach to fighting COVID? What actions did China take in the three-year period between its victory in Wuhan and its re-opening? And can China achieve a solid recovery in 2023?

Through the eyes of frontline intensive care specialists, village doctors, community workers, volunteers and decision makers, the documentary reveals the answers.

Reflecting on China’s Three-year COVID Battle in Through the Storm
Reflecting on China’s Three-year COVID Battle in Through the Storm

THE WINDOWS OF OPPORTUNITIES

What China faced in early 2020 was the original strain of the novel coronavirus, which was far more virulent and deadly than the current Omicron strain. At the time, there were just 63,000 ICU beds for a population of 1.4 billion. Even China’s finest medical minds seemed helpless in the face of this unknown enemy.

The dire situation faced by Wuhan could have been repeated all across the country. But thanks to China’s rigorous COVID policies, a national disaster was averted.

Nearly 120,000 ICU beds have been added since the start of the outbreak. As a result, China now has more ICU beds per 100,000 people than developed countries such as Britain, Japan, Spain and France. Also, the country’s medical staff have accumulated experience and skill in dealing with the Omicron strain, adopting a series of updated treatment protocols and diagnostic techniques. In the course of two years, China vaccinated over 91% of its population, with special emphasis on the elderly.

THE BARRIERS

In the three years that followed the initial outbreak, much has changed. From stringent community lockdowns, mass PCR testing and the setting up of makeshift hospitals, the experience gained and measures adopted in Wuhan were embraced and perfected.

Since January 10, 2020, there have been a total of 250 days when no new COVID cases were reported. Zhong Nanshan, China’s leading expert on respiratory diseases, estimates that over 20 million lives have been saved, as a result of China’s stringent anti-COVID policies.

The Chinese people were always confident that they could defeat the virus.

Following the Alpha, Delta and Gamma variants came the Omicron strain, which infects the human body 70 times faster, but with symptoms that are far less severe.

The evolving variants brought greater challenges. In response, China regularly adjusted its prevention and control measures, until eventually the decision was taken to make a major shift in its COVID policies at the end of 2022.

BACK ON COURSE

Throughout the pandemic, China remained a major contributor to global economic growth. Over the past five years, in spite of the global instability, the pandemic and a domestic slowdown, China has still managed to achieve average annual GDP growth of 5%.

A major beneficiary of the easing of the anti-COVID measures has been the movie industry. Box-office receipts during the seven-day Spring Festival holiday were the second-highest ever on record, at one billion US dollars. During the same period, over 300 million passenger journeys were recorded on the country’s transport network, generating revenue of 56 billion US dollars for the tourism industry, a 30% year-on-year increase.

The IMF raised the estimate for China’s 2023 GDP growth from 4.4% to 5.2%. Morgan Stanley is even more optimistic, improving its growth outlook to 5.7% in a research note released in January, 0.3 percentage point higher than its previous estimate.

Although the world is now gradually recovering from the pandemic, the novel coronavirus is still present. To secure a more certain future for humankind, greater, more effective and broader global cooperation is essential.